Sleep Disorders in Chronic Liver Disease

Cruz, Sharon De; Espiritu, Joseph; Zeidler, Michelle; Wang, Tisha S.

doi:10.1055/s-0032-1301732

Cited by 42 publications

(23 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sleep-related complaints and disturbances are increasingly recognized in the setting of chronic liver disease and have recently been shown to be an important prognostic factor in patients with advanced chronic liver disease. 15 In a study conducted by Gencdal and others on 131 cirrhotic patients and 18 healthy volunteers, they found that sleep disorders were common in cirrhotic patients, most in Child C patients. 16 Also, Vinicius et al, studied sleep aspects and parameters in 42 cirrhotic patients, and 42 controls and assessed the role of liver dysfunction severity in polysomnographic results.…”

Section: Discussionmentioning

confidence: 97%

Prevalence of sleep disorders among ESRD patients

Ezzat

Mohab

2015

Renal Failure

View full text Add to dashboard Cite

Sleep disorders are common among the patients undergoing dialysis in end stage renal disease (ESRD). Although variable, their prevalence has been reported to be higher when compared to the general population. The most frequently reported complaints are insomnia, restless leg syndrome (RLS), sleep-disordered breathing and excessive daytime sleepiness (EDS). The aim of this study was to assess the prevalence of sleep disorders in end stage renal disease patients on regular hemodialysis (group I with 30 patients) and CKD patients (group II with 30 patients) in comparison to 30 normal population (control group). In addition to laboratory investigations which included creatinine clearance using Cockroft and Gault formula, hemoglobin level (Hb), blood urea, serum creatinine, serum albumin, serum calcium and phosphorus and lipid profile, all subjects underwent one night of laboratory-based polysomnography (PSG) consisting of a standard montage of electroencephalography (EEG) (C3/A1 and O2/C3 or O1/C4), monopolar left and right electrooculography (EOG) referenced to the opposite mastoid, surface mentalis electromyography (EMG), respiratory airflow (measured by thermistor) and effort (piezoelectric sensors), electrocardiography (ECG), anterior tibialis EMG and pulse oximetry. For hemodialysis subjects, this study was performed on a night immediately following hemodialysis treatment. The results showed that patients on hemodialysis have sleep disorders, and that sleep disorders are common in group I and II than control group. The percentage of sleep disorders in hemodialysis patients were as follows: insomnia (69%), followed by obstructive sleep apnea syndrome OSAS (24%), RLS and periodic limb movement PLM (18%), nightmares (13%), EDS (12%), sleepwalking (2%), possible rapid eye movement behavior disorders RED (2%), possible narcolepsy (1.4%). While the percentage of sleep disorders in CKD patients were as follows: insomnia (54%), followed by RLS (19%), PLM (12%), OSAS (16%), nightmares (15%), EDS (15%), sleepwalking (4%), possible RBD (3%), possible narcolepsy (1%). There was inverse correlation between sleep disorders and Hb, albumin and creatinine clearance; also there was positive correlation between sleep disorder and phosphorus. We concluded that the sleep disorders are common in CKD patients either on conservative management or on regular hemodialysis. Treatment of anemia, hyperphosphatemia and hypoalbuminemia may improve sleep disorders among those patients.

show abstract

Section: Discussionmentioning

confidence: 97%

Prevalence of sleep disorders among ESRD patients

Ezzat

Mohab

2015

Renal Failure

View full text Add to dashboard Cite

show abstract

“…Sleep disorders, fatigue and daytime somnolence are also known symptoms for other types of chronic liver diseases such as cirrhosis, chronic hepatitis C, Wilson disease and NAFLD itself (47).…”

Section: European Journal Of Endocrinologymentioning

confidence: 99%

Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma

Hoffmann

Bootsveld

Gebhardt

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Hypothalamic obesity in childhood craniopharyngioma (CP) patients carries a high risk for development of metabolic syndrome. In metabolic syndrome, the development of nonalcoholic fatty liver disease (NAFLD) is known. The aim of this study is to detect the risk for NAFLD in childhood-onset CP. Design: This cross-sectional study included liver computed tomography (CT); ultrasound analysis of abdomen; measurements of serum parameters, height, weight and body composition; and daily medication of patients with childhood-onset CP. Methods: A total of 384 patients recruited in trials HIT Endo and KRANIOPHARYNGEOM 2000 were analyzed. Ninety-four survivors were included by fulfilling the criteria of proven hypothalamic involvement (HI), a minimum time interval of 5 years between diagnosis and study, and a minimum age of 18 years at the time of evaluation. A total of 19 patients agreed to participate. To quantify the degree of steatosis hepatis, analyses of liver density were performed once by non-contrasted CT of liver sections. Results: NAFLD occurs in about 50% of CP patients with HI and is associated with elevated liver enzymes and homeostasis model assessment index. BMI is not an effective predictive factor but body fat mass measured by near-infrared spectroscopy (NIRS) is. Over half of CP patients (60%) with NAFLD are treated with stimulating agents, with risk of hepatic side effects. Conclusions: NAFLD is a major adverse late effect in childhood-onset CP. NIRS rather than BMI should be used to measure body composition and predict NAFLD. Stimulating agents for treatment of fatigue and daytime sleepiness in CP should be prescribed judiciously.

show abstract

“…A certain drug can be therapeutic and safe when taken at one time, but insufficient or poorly tolerated at another. Circadian rhythm abnormalities are associated with a variety of types of chronic liver diseases including hepatitis C, primary biliary cirrhosis, Wilson disease, and fibrosis and hepatic encephalopathy [115]. …”

Section: Recent Developmentmentioning

confidence: 99%

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Guan

2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There is a vast body of knowledge which is ever-increasing about the treatment of liver disease with alternative and complementary medicine for which hundreds of thousands of literatures have been documented. Liver disease is a general term. This term covers all the potential problems that cause the liver to fail to perform its specified operations. Liver disease has a variety of presentations and causes a great public health problem worldwide which threatens the wellness of billions of people. Incidences of many types of liver disease are currently rising. Although there is still a debate about the entity of alternative and complementary medicine, it is now widely used and it is improving. And it covers the shortages and compensates for the weaknesses of conventional methods in the treatment of liver diseases. Alternative and complementary medicine for liver diseases provides benefits by regulating immunity, controlling disease progression, improving quality of life, and prolonging survival. This paper reviews the increasing interest and growing research into alternative and complementary medicine for liver diseases, with a look at the rough classification, principle of management, evidence-based applications, and issues for prescription and perspectives.

show abstract

Sleep Disorders in Chronic Liver Disease

Cited by 42 publications

References 85 publications

Prevalence of sleep disorders among ESRD patients

Prevalence of sleep disorders among ESRD patients

Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma

A Current Update on the Rule of Alternative and Complementary Medicine in the Treatment of Liver Diseases

Contact Info

Product

Resources

About